An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
Condition(s):Diabetes Mellitus, Type 2Last Updated:June 14, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Diabetes Mellitus, Type 2Last Updated:June 14, 2017Completed
Condition(s):HealthyLast Updated:June 6, 2016Completed
Condition(s):Healthy SubjectsLast Updated:September 6, 2018Completed
Condition(s):CancerLast Updated:January 26, 2016Withdrawn
Condition(s):Infection, Human Immunodeficiency VirusLast Updated:July 27, 2017Completed
Condition(s):BioequivalenceLast Updated:May 25, 2011Completed
Condition(s):Ovarian Cancer Risk; Risk-reducing Surgery; Fallopian Tube Fimbriae; Ovarian Cortical Inclusion CystsLast Updated:June 25, 2020Completed
Condition(s):Oral ContraceptiveLast Updated:February 23, 2018Completed
Condition(s):Healthy Female VolunteersLast Updated:September 25, 2023Completed
Condition(s):Oral ContraceptiveLast Updated:September 10, 2014Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.